Avian Influenza Virus Type A N5 subtype antibody and antigen (recombinant protein)

Diagnostic anti-Avian Influenza Virus Type A N5 subtype antibodies pairs and antigen for animal health (animal Avian/Bird/Poultry infectious disease Avian influenza) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Target products collectionGo to Avian/Bird/Poultry disease testing products collection >>


Product information

Catalog No. Description US $ Price (per mg)
GMP-VT-P217-Ag01 Recombinant Avian Influenza Virus Type A N5 subtype protein $3090.00
GMP-VT-P217-Ab01 Anti-Avian Influenza Virus Type A N5 subtype mouse monoclonal antibody (mAb) $3090.00
GMP-VT-P217-Ab02 Anti-Avian Influenza Virus Type A N5 subtype mouse monoclonal antibody (mAb) $3090.00

Size: 1mg | 10mg | 100mg



Product Description

Cat No. GMP-VT-P217-Ag01
Product Name Recombinant Avian Influenza Virus Type A N5 subtype protein
Pathogen Avian Influenza Virus Type A N5 subtype
Expression platform E.coli
Isotypes Recombinant Antigen
Bioactivity validation Anti-Avian Influenza Virus Type A N5 subtype antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Avian Influenza Virus Type A N5 subtype level test of animal Avian/Bird/Poultry infectious disease with Avian influenza.
Tag His
Product description Recombinant Avian Influenza Virus Type A N5 subtype proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No. GMP-VT-P217-Ab01,GMP-VT-P217-Ab02
Pathogen Avian Influenza Virus Type A N5 subtype
Product Name Anti-Avian Influenza Virus Type A N5 subtype mouse monoclonal antibody (mAb)
Expression platform CHO
Isotypes Mouse IgG
Bioactivity validation Recombinant Avian Influenza Virus Type A N5 subtype antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Avian Influenza Virus Type A N5 subtype antibodies in Avian Influenza Virus Type A N5 subtype level test of animal Avian/Bird/Poultry infectious disease with Avian influenza.
Product description Anti-Avian Influenza Virus Type A N5 subtype mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Avian Influenza Virus Type A N5 subtype antibodies./td>
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Validation Data


    Click to get more Data / Case study about the product.



    Pathogen


    The Avian Influenza Virus Type A N5 subtype is a member of the larger family of influenza viruses, known as Orthomyxoviridae. These viruses are known for their segmented negative-sense RNA genome, which consists of eight segments that code for various proteins required for their replication and spread.

    The genome of Avian Influenza Virus Type A N5 subtype encodes for eleven proteins, two of which are highly significant for the virus' ability to infect and spread efficiently. These two proteins are hemagglutinin (HA) and neuraminidase (NA). The HA protein is responsible for binding the virus to host cells and facilitating the viral entry into the cells. The NA protein, on the other hand, helps the release of new virus particles from infected cells and facilitates the spread of the virus within the host organism.

    Avian Influenza Virus Type A N5 subtype primarily infects birds, particularly domestic poultry such as chickens and turkeys. The pathogen can also infect other avian species such as ducks and geese. Wild birds also act as natural reservoirs for this virus. Human infections with this virus have been reported occasionally, often through contact with infected birds or their contaminated environments. The majority of human infections are sporadic and have occurred in people exposed to infected birds or contaminated environments. However, there is a concern that this virus can mutate and adapt to efficiently spread from human to human, causing pandemics similar to the ones caused by the H1N1 and H5N1 viruses in the past.

    The clinical manifestation of infection with the Avian Influenza Virus Type A N5 subtype can vary depending on the host species and the virulence of the virus strain. In birds, the symptoms can range from asymptomatic infections to severe respiratory illness, resulting in high mortality rates. However, some strains of this virus are lethal to humans, with severe respiratory and systemic symptoms that may result in death. The symptoms of human infection can range from mild fever and cough to severe respiratory distress syndrome, multi-organ failure, and even death.

    The diagnosis of Avian Influenza Virus Type A N5 subtype infection relies on various methods. Nucleic acid-based assays such as the reverse transcription-polymerase chain reaction (RT-PCR) targeting the HA and NA genes are the most common methods to identify the virus in clinical and environmental samples. Other diagnostic methods include immunological assays that detect antibodies against the virus, such as enzyme-linked immunosorbent assay (ELISA) and hemagglutination inhibition assay (HIA).

    In conclusion, the Avian Influenza Virus Type A N5 subtype is a pathogenic virus that primarily affects birds, but also has the potential to infect humans. The virus gets transmitted through contact with infected birds or contaminated environments, and the symptoms of infection can range from mild to severe respiratory distress. Early diagnosis and implementation of adequate control measures are crucial to containing the spread of this virus, thereby minimizing its impact on both human and animal health.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.